Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Angle, Better Therapeutics, Daxor, Endoquest Robotics, Lumiradx, Pulse Biosciences, Roche, Simbiosys.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: CGBio, Endosound, Pulnovo.
Two big pharma firms placed high offers on Dec. 26 to acquire companies focused on radiopharmaceuticals and cell therapies in what Evercore ISI analysts are calling a “good sign for the end of the year.”
A recent survey on the performance of publicly listed Korean health care firms in 2023 unveiled a still floundering med-tech sector, although local pharmaceutical companies seemed to rebound after the COVID-19 pandemic.
Researchers from the University of Minnesota are seeking patent protection and possible collaborators for their development of three-dimensional (3D) printed skin-wearable photodetector devices.
Echoing trends seen last year, the med-tech industry concluded 2023 with a continued surge in deal value juxtaposed against a more substantial decline in M&A value. Deal value for the year, including licensings, collaborations and joint ventures, reached $10.63 billion from 1,656 deals, the highest annual value in BioWorld’s records.
RSS
